{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:28:26Z","timestamp":1791404906435,"version":"4.3.3"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":4868,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1995,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>OBJECTIVE Short\u2010term GH replacement in hypopituitary adults increases bone turnover; data on the consequences of longer\u2010term GH treatment are limited. We report on the effects of 12\u201318 months of GH replacement treatment with biosynthetic human GH on bone metabolism and bone mass in hypopituitary adults.<\/jats:p><jats:p>DESIGN Patients were studied before and after GH treatment for 12 months (<jats:italic>n<\/jats:italic>= 11) and 18 months (<jats:italic>n<\/jats:italic>= 27) respectively in an open trial. GH dose was 0\u00b704\u00b10\u00b701 IU\/kg daily.<\/jats:p><jats:p>MEASUREMENTS Plasma calcium, phosphate and intact PTH concentrations, 24\u2010hour urinary calcium excretion, 3 markers of bone formation (total alkaline phosphatase, osteocalcin and procollagen 1 carboxy terminal peptide (P1CP)) and serum concentration of carboxyterminal cross\u2010linked telopeptide of type 1 collagen (ICTP), as a marker of bone resorption, were measured at 6\u2010month intervals. Lumbar splne and total body bone mineral mass was measured by dual\u2010energy X\u2010ray absorptiometry.<\/jats:p><jats:p>RESULTS Small increases were observed in plasma calcium and phosphate concentrations at 12 months of GH therapy but the differences at 18 months were not statistically significant. Serum intact PTH concentration did not change. Plasma total alkaline phosphatase increased significantly on GH from 75 \u00b1 26 to 92 \u00b1 30 (<jats:italic>P<\/jats:italic>&lt;0\u00b701) and 85\u00b131 U\/I (NS) at 12 and 18 months respectively. Serum osteocalcin increased from 6\u00b75 \u00b1 3\u00b77 to 15\u00b77 \u00b1 6\u00b72 (<jats:italic>P<\/jats:italic>&lt;0\u00b70001) and 16\u00b76\u00b15\u00b77 \u03bcg\/l (<jats:italic>P<\/jats:italic>&lt;0\u00b7001) at 12 and 18 months respectively and P1CP increased significantly from 106\u00b70 \u00b1 47\u00b73 \u03bc\/l to 165\u00b75 \u00b1 95\u00b73 (<jats:italic>P<\/jats:italic>&lt; 0\u00b70001) and 177\u00b72 \u00b1 72\u00b72 \u03bcg\/l (<jats:italic>P<\/jats:italic>&lt;0\u00b701) at 12 and 18 months respectively. Plasma ICTP concentration increased also from 3\u00b74 \u00b1 1\u00b78 to 7\u00b73 \u00b1 3\u00b74 (<jats:italic>P<\/jats:italic> &lt; 0\u00b70001) and 7\u00b70 \u00b1 2\u00b77 \u03bcg\/l (<jats:italic>P<\/jats:italic>&lt;0\u00b7003) at 12 and 18 months of GH therapy respectively. No significant change was observed in total body or lumbar splne bone mass, over the 18 months of GH treatment<\/jats:p><jats:p>CONCLUSIONS Replacement therapy with GH in hypopituitary adults for 6\u201318 months produced a sustained increase in bone turnover (both formation and resorption). Bone mass was maintained but did not increase over the study period.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1995.tb01872.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T10:29:55Z","timestamp":1205749795000},"page":"249-254","source":"Crossref","is-referenced-by-count":46,"title":["The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults*"],"prefix":"10.1111","volume":"42","author":[{"given":"Salem A.","family":"Beshyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fairney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond G.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.2.309"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb01860.x"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02601.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.2.356"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb03936.x"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1300451"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02287.x"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-56-6-1246"},{"key":"e_1_2_1_10_1","first-page":"387","article-title":"Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism","volume":"126","author":"Degerblad M.","year":"1992","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_11_1","first-page":"326","article-title":"Long term follow\u2010up of metacarpal cortical thickness and bone mineral density in panhypopituitarism","volume":"32","author":"Elgindy N.","year":"1991","journal-title":"Radiological Diagnosis"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.6.1452"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-49-2-185"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-53-4-818"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.3.669"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.12.1472"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-4-916"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.74.1.118"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00571329"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-2-519"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.5.1344"},{"key":"e_1_2_1_22_1","first-page":"163","article-title":"The contribution of bone histology to understanding the pathogenesis and improving the management of osteoporosis","volume":"5","author":"Parfitt A.M.","year":"1982","journal-title":"Journal of Clinical Investigation"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00929.x"},{"key":"e_1_2_1_24_1","first-page":"201","article-title":"Reduced bone mineral content in adult patients with growth hormone deficiency","volume":"129","author":"Rosen T.","year":"1993","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007053230101"},{"key":"e_1_2_1_26_1","first-page":"41","article-title":"Quadriceps strength before and during growth hormone treatment in hypopituitary adults: relationship to changes in lean body mass and IGF\u2010I","volume":"1","author":"Rutherford O.M.","year":"1994","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212605"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1991.tb11739.x"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348952"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00930.x"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1002115"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb02387.x"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02901.x"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01797616"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1995.tb01872.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1995.tb01872.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T02:07:39Z","timestamp":1698286059000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1995.tb01872.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["10.1111\/j.1365-2265.1995.tb01872.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb01872.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}